Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more
Tianjin Tianyao Pharmaceuticals Co Ltd (600488) - Total Assets
Latest total assets as of September 2025: CN¥5.74 Billion CNY
Based on the latest financial reports, Tianjin Tianyao Pharmaceuticals Co Ltd (600488) holds total assets worth CN¥5.74 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tianjin Tianyao Pharmaceuticals Co Ltd - Total Assets Trend (1998–2024)
This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tianjin Tianyao Pharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Tianjin Tianyao Pharmaceuticals Co Ltd's total assets of CN¥5.74 Billion consist of 31.7% current assets and 68.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.2% |
| Accounts Receivable | CN¥484.33 Million | 8.5% |
| Inventory | CN¥651.92 Million | 11.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥530.57 Million | 9.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1998–2024)
This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Tianyao Pharmaceuticals Co Ltd's current assets represent 31.7% of total assets in 2024, a decrease from 62.0% in 1998.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2024, up from 6.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is inventory at 11.4% of total assets.
Tianjin Tianyao Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Tianjin Tianyao Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Tianjin Tianyao Pharmaceuticals Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Tianjin Tianyao Pharmaceuticals Co Ltd generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Tianjin Tianyao Pharmaceuticals Co Ltd generates $ 2.34 in net profit.
Tianjin Tianyao Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.74 | 1.48 | 1.04 |
| Quick Ratio | 1.19 | 0.95 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥846.27 Million | CN¥ 682.52 Million | CN¥ 81.03 Million |
Tianjin Tianyao Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tianjin Tianyao Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -7.2% |
| Total Assets | CN¥5.70 Billion |
| Market Capitalization | $271.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Tianyao Pharmaceuticals Co Ltd's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tianjin Tianyao Pharmaceuticals Co Ltd's assets decreased by 7.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tianjin Tianyao Pharmaceuticals Co Ltd (1998–2024)
The table below shows the annual total assets of Tianjin Tianyao Pharmaceuticals Co Ltd from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.70 Billion | -7.23% |
| 2023-12-31 | CN¥6.14 Billion | -7.64% |
| 2022-12-31 | CN¥6.65 Billion | +4.82% |
| 2021-12-31 | CN¥6.35 Billion | +2.74% |
| 2020-12-31 | CN¥6.18 Billion | +16.94% |
| 2019-12-31 | CN¥5.28 Billion | +10.01% |
| 2018-12-31 | CN¥4.80 Billion | +12.08% |
| 2017-12-31 | CN¥4.28 Billion | +42.69% |
| 2016-12-31 | CN¥3.00 Billion | -1.04% |
| 2015-12-31 | CN¥3.03 Billion | +4.71% |
| 2014-12-31 | CN¥2.90 Billion | -6.90% |
| 2013-12-31 | CN¥3.11 Billion | +24.87% |
| 2012-12-31 | CN¥2.49 Billion | +3.11% |
| 2011-12-31 | CN¥2.42 Billion | -17.23% |
| 2010-12-31 | CN¥2.92 Billion | +11.29% |
| 2009-12-31 | CN¥2.62 Billion | +2.01% |
| 2008-12-31 | CN¥2.57 Billion | +11.08% |
| 2007-12-31 | CN¥2.32 Billion | -4.53% |
| 2006-12-31 | CN¥2.43 Billion | +22.61% |
| 2005-12-31 | CN¥1.98 Billion | +29.40% |
| 2004-12-31 | CN¥1.53 Billion | -4.76% |
| 2003-12-31 | CN¥1.60 Billion | +13.10% |
| 2002-12-31 | CN¥1.42 Billion | +25.13% |
| 2001-12-31 | CN¥1.13 Billion | +125.55% |
| 2000-12-31 | CN¥502.78 Million | +22.40% |
| 1999-12-31 | CN¥410.77 Million | +41.68% |
| 1998-12-31 | CN¥289.93 Million | -- |